However, in our case the a priori sample size calculation was based on previously published monocentric treatment effects on infarct volume at Day 3 after tMCAO.14 Consequently, our pRCT was not powered to assess effects of an IL-17A neutralization on long-term neurological outcome as it is standard practice in human stroke studies.39 Another major limitation of our study is the exclusive analysis of young male mice but not female, aged or co-morbid mice. The gene discussed is IL17A; the disease is stroke disorder.